Safety and Efficacy of a Novel Balloon Angiographic Catheter for Coronary Venography During Left Ventricular Lead Implantation: A Prospective Multicenter Single-arm Trial
In a prospective multicenter single-arm trial involving 97 patients, the novel LeesCa™ balloon angiographic catheter demonstrated 100% device success and a 98.97% procedural success rate with a low adverse event profile, confirming its safety and efficacy for coronary venography during left ventricular lead implantation for cardiac resynchronization therapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Heart failure is a condition where the heart muscle becomes too weak to pump blood effectively throughout the body. For many patients, the problem is not just weakness, but a lack of coordination; the left and right sides of the heart, or different sections of the left side, beat out of sync. To fix this, doctors use a treatment called cardiac resynchronization therapy. This involves implanting a small device, similar to a pacemaker, that sends electrical signals to the heart to make all its parts contract together again. The success of this treatment depends heavily on placing a tiny wire, known as a lead, into a specific vein on the surface of the left ventricle. Finding the right vein is like navigating a complex, winding river system; if the wire cannot reach the ideal spot, the therapy may not work, and the patient remains sick.
The challenge for doctors is that these veins are often small, twisted, and difficult to see clearly on X-ray images. Standard tools used to inject dye and map the veins sometimes fail to provide a clear picture, forcing doctors to repeat injections, which increases radiation exposure and the amount of dye the patient receives. To solve this, researchers tested a new, specialized catheter designed to improve the view of these difficult veins. This device, called the LeesCa balloon angiographic catheter, works by inflating a tiny balloon inside the main vein to block blood flow temporarily. This blockage allows the contrast dye to stay in place and fill the smaller, twisting branches completely, creating a sharp, detailed map for the surgeon to follow.
A team of doctors from four major hospitals in China recently conducted a large study to see if this new tool works safely and effectively in real-world settings. They enrolled 97 patients who needed the left ventricular lead implanted. The researchers used the new balloon catheter to perform the venography, which is the process of taking X-ray pictures of the veins. The primary goal was to see if the device could successfully reach the target area and provide a clear image in every single case. The results were striking: the device worked perfectly in all 97 patients, achieving a 100 percent success rate in creating the necessary images. This was significantly better than the 93 percent success rate the researchers had set as their target before the study began.
Beyond just taking pictures, the study measured how well the device helped the overall procedure. In 96 out of the 97 patients, the doctors were able to successfully place the pacing lead into the heart after using the catheter. The one patient who could not receive the lead had veins that were simply too small and twisted, a problem with the patient's own anatomy rather than a failure of the tool. On average, the time it took to implant the lead was about 18 minutes. The amount of contrast dye used was roughly 30 milliliters, and the total time the X-ray machine was active was about 1,113 seconds. These numbers suggest that the new tool allows the procedure to be completed efficiently without excessive use of resources.
Safety was a major focus of the investigation. The researchers closely monitored the patients for any complications during the hospital stay and for up to seven days after the procedure. Only three minor issues occurred among the entire group: a small bruise at the needle entry site, a mild reaction to the dye, and a brief fainting spell caused by a nervous system reflex. None of these events were caused by the catheter itself, and none required serious medical intervention. No patients suffered from serious complications like bleeding inside the heart, damage to the veins, or the device breaking apart. Every single catheter was removed from the body intact, showing that the tool is robust and reliable.
The doctors who performed the procedures also rated the device on how easy it was to handle. They gave it high marks for its ability to move through the veins, its strength in supporting the wires, and its overall performance. Every operator felt the device met the needs of the surgery. The study concluded that this new balloon catheter is a safe and effective way to visualize the coronary veins during heart resynchronization therapy. It provides a clear view of the anatomy, helps guide the lead to the correct spot, and does so without increasing the risks to the patient. While the study was limited to a short follow-up period and did not compare the new tool directly against old ones in a head-to-head race, the results strongly suggest that this device is a valuable addition to the tools doctors use to treat heart failure.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.